Ironwood Pharmaceuticals, Inc.

NasdaqGS:IRWD 株式レポート

時価総額:US$642.2m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Ironwood Pharmaceuticals マネジメント

マネジメント 基準チェック /34

Ironwood Pharmaceuticals'の CEO はTom McCourtで、 Mar2021年に任命され、 の在任期間は 3.25年です。 の年間総報酬は$ 7.58Mで、 11%給与と89%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.32%を直接所有しており、その価値は$ 2.92M 。経営陣と取締役会の平均在任期間はそれぞれ2.6年と5.2年です。

主要情報

Tom McCourt

最高経営責任者

US$7.6m

報酬総額

CEO給与比率11.0%
CEO在任期間3.5yrs
CEOの所有権0.3%
経営陣の平均在職期間2.9yrs
取締役会の平均在任期間5.4yrs

経営陣の近況

Recent updates

Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Aug 16
Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough

Jun 27
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough

Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC

Jun 20

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Feb 16
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential

Jan 31

Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Dec 19
Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

Jul 25
Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Apr 18
An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Mar 28
Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Ironwood Pharmaceuticals: Rinse, Wash And Repeat

Oct 05

These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Sep 28
These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh

Jul 29

CEO報酬分析

Ironwood Pharmaceuticals の収益と比較して、Tom McCourt の報酬はどのように変化したか?
日付総報酬給与会社業績
Jun 30 2024n/an/a

US$9m

Mar 31 2024n/an/a

-US$1b

Dec 31 2023US$8mUS$834k

-US$1b

Sep 30 2023n/an/a

-US$952m

Jun 30 2023n/an/a

-US$917m

Mar 31 2023n/an/a

US$182m

Dec 31 2022US$8mUS$805k

US$175m

Sep 30 2022n/an/a

US$168m

Jun 30 2022n/an/a

US$173m

Mar 31 2022n/an/a

US$527m

Dec 31 2021US$9mUS$732k

US$528m

Sep 30 2021n/an/a

US$530m

Jun 30 2021n/an/a

US$509m

Mar 31 2021n/an/a

US$143m

Dec 31 2020US$3mUS$576k

US$106m

Sep 30 2020n/an/a

US$111m

Jun 30 2020n/an/a

US$97m

Mar 31 2020n/an/a

US$84m

Dec 31 2019US$5mUS$511k

US$59m

Sep 30 2019n/an/a

US$19m

Jun 30 2019n/an/a

-US$153m

Mar 31 2019n/an/a

-US$173m

Dec 31 2018US$2mUS$465k

-US$194m

Sep 30 2018n/an/a

-US$190m

Jun 30 2018n/an/a

-US$71m

Mar 31 2018n/an/a

-US$108m

Dec 31 2017US$2mUS$450k

-US$55m

報酬と市場: Tomの 総報酬 ($USD 7.58M ) は、 US市場 ($USD 3.39M ) の同規模の企業の平均を上回っています。

報酬と収益: Tomの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Tom McCourt (67 yo)

3.5yrs

在職期間

US$7,583,270

報酬

Mr. Thomas A. McCourt, also known as Tom, serves as Director at Pliant Therapeutics, Inc. since March 08, 2023. He serves as Chief Executive Officer and Director of Ironwood Pharmaceuticals, Inc. since Jun...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Thomas McCourt
CEO & Director3.5yrsUS$7.58m0.32%
$ 2.1m
Sravan Emany
Senior VP2.8yrsUS$2.76m0.098%
$ 631.5k
John Minardo
Senior VP3.1yrsUS$2.44m0.080%
$ 511.3k
Michael Shetzline
Chief Medical Officer5.7yrsUS$2.60m0.16%
$ 1.0m
Andrew Davis
Senior VP & Chief Business Officer2.7yrsUS$2.67m0.10%
$ 671.5k
Ronald Silver
Corporate Controller & Principal Accounting Officer5.4yrsデータなし0.043%
$ 273.1k
Greg Martini
Vice President of Strategic Finance & Investor Relationsno dataデータなしデータなし
Beth Calitri
VP of Corporate Communications & Media Relations2.7yrsデータなしデータなし
Mike Nanfito
Vice President of Sales & Sales Excellence3yrsデータなしデータなし
Susanna Huh
VP & Head of Clinical Development2yrsデータなしデータなし
Jana Noeldeke
Basel Site Head & Apraglutide Lifecycle Leader1.7yrsデータなしデータなし
Matt Roache
Director of Investor Relationsno dataデータなしデータなし

2.9yrs

平均在職期間

47yo

平均年齢

経験豊富な経営陣: IRWDの経営陣は 経験豊富 であると考えられます ( 2.6年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Thomas McCourt
CEO & Director3.3yrsUS$7.58m0.32%
$ 2.1m
Jay Shepard
Independent Director3.8yrsUS$300.71k0.079%
$ 508.8k
Perry Halushka
Member of Pharmaceuticals Advisory Committeeno dataデータなしデータなし
Alexander Denner
Independent Director3.8yrsUS$300.69k0.095%
$ 611.5k
Mark Currie
Independent Director5.4yrsUS$300.71k0.36%
$ 2.3m
Andrew Dreyfus
Independent Director8.4yrsUS$310.71k0.12%
$ 756.7k
Michael Mendelsohn
Member of Pharmaceutical Advisory Committee7.6yrsデータなしデータなし
Catherine Moukheibir
Independent Director5.4yrsUS$310.69k0.046%
$ 293.2k
Julie McHugh
Independent Chairman of the Board10.6yrsUS$335.71k0.10%
$ 658.7k
Marla Kessler
Independent Director5.4yrsUS$300.71k0.076%
$ 486.0k
Jon Duane
Independent Director5.4yrsUS$305.71k0.091%
$ 584.3k

5.4yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: IRWDの 取締役会経験豊富 であると考えられます ( 5.2年の平均在任期間)。